• Je něco špatně v tomto záznamu ?

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

D. Placha, J. Jampilek

. 2021 ; 13 (1) : . [pub] 20210106

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010734

Grantová podpora
APVV-17-0373 Slovak Research and Development Agency
CZ.02.1.01/0.0/0.0/17\_049/0008441 Ministry of Education of the Czech Republic:SGS project SP2020/70

Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010734
003      
CZ-PrNML
005      
20210716100353.0
007      
ta
008      
210413s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics13010064 $2 doi
035    __
$a (PubMed)33419176
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Placha, Daniela $u Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic ; Centre ENET, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
245    10
$a Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems / $c D. Placha, J. Jampilek
520    9_
$a Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Jampilek, Josef $u Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, 842 15 Bratislava, Slovakia ; Division of Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33419176 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210716100353 $b ABA008
999    __
$a ind $b bmc $g 1649922 $s 1131110
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 1 $e 20210106 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a APVV-17-0373 $p Slovak Research and Development Agency
GRA    __
$a CZ.02.1.01/0.0/0.0/17\_049/0008441 $p Ministry of Education of the Czech Republic:SGS project SP2020/70
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Možnosti archivace